Hepatitis/MASH

Velpatasvir is a pangenotypic NS5A inhibitor for patients with hepatitis C genotypes 1 through 6 of the virus.

For patients with hepatitis C seeking modern treatment options, many health plans force health care professionals use criteria that are clinically unsound.

Investigators question if hepatitis A virus originated in animals.

Hepatitis C incidence rate among HIV-positive men who have sex with men grew three-fold from 1991 to 2010.

Drug that targets interaction with RNA does not damage other proteins.

An OTC drug used to alleviate allergy symptoms could treat hepatitis C virus infection as well.

An investigational combination of 3 interferon-free drugs has proven effective at treating hepatitis C virus.

Although hepatitis C virus medications are often costly to many patients, recent study results suggest that treating the disease can reduce absenteeism and increase productivity.

Concerns raised over treatment that fights fungal infections in lung transplant patients.

Improvements can be made to provide procedure-specific national benchmarks for postsurgical outcomes.

Pharmacists are ideally situated to help patients beat hepatitis C.

Entecavir treats chronic hepatitis B infection in adults with evidence of active viral replication.

Access to high cost curative antiviral HCV drugs remains a challenge for patients.

Findings may better predict organ rejection before transplantation.

An HCV infection may cause more than just liver damage.

Research may lead to a gel that instantly destroys viral particles.

Research could aid drug discovery.

Bill authorizes the VA to spend as much as $500 million for hepatitis C treatments.

Comorbidities lead to more complex treatment and higher costs.

Additional benefit from dasabuvir and combination of ombitasvir/paritaprevir/ritonavir found in pretreated genotype 1b hepatitis C patients without cirrhosis.

Hepatitis C drugs with high cure rates create new dilemma for people in need of transplantation.

A lymphotoxin-beta receptor inhibitor may stop the spread of the disease.

Single-tablet combination was previously granted two breakthrough therapy designations.

The FDA has granted priority review to Merck's chronic hepatitis C virus (HCV) treatment candidate grazoprevir/elbasvir.

Liver damage progresses at a more rapid pace in patients with HIV.